BioSpace News Archive

GBS, a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, announced its participation in the following investor conferences in the month of September and invites investors to join virtually.

Revolution Medicines, Inc. (Nasdaq: RVMD), today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will deliver a corporate presentation as part of the H.C. Wainwright 23rd Annual Global Investment Conference.

Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in targeted C3 therapies, announced that the company approved the grant of equity awards to one new employee with a grant date of September 1, 2021, as equity inducement awards outside of the company’s 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the company.

Wave Life Sciences Ltd. announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to give a pre-recorded presentation at the H.C. Wainwright 23rd Annual Global Investment Conference, which will be made available for on-demand viewing on Monday, September 13, 2021 at 7:00 a.m. ET.

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that an abstract featuring initial clinical data from the BRILLIANCE clinical trial of EDIT-101 has been selected for an oral presentation at the XIXth International Symposium on Retinal Degeneration (RD2021) being held in Nashville, Tenn., and virtually September 28 – October 2, 2021.

Altimmune, Inc., a clinical-stage biopharmaceutical company, announced that members of the management team will present during a fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference, being held virtually on September 13-15, 2021.

REGENXBIO Inc. announced it will participate in the following investor conferences, which will each be held in a virtual meeting format.

IntelGenx Corp. (TSX V:IGX)(OTCQB:IGXT) (the “Company” or “IntelGenx”) today announced that Exeltis Healthcare S.L. (“Exeltis”), its commercialization partner in the European Union (“EU”) for RIZAPORT®, a unique for the treatment of acute migraines, has launched the product in Spain.

Puma Biotechnology, Inc., a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at the virtual H.C. Wainwright 23rd Annual Global Investment Conference, which will be held September 13-15, 2021.

Medpace Holdings, Inc. announced that it will report its third quarter 2021 financial results after the market close on Monday, October 25, 2021.